Expression analysis using PAM50 criteria shows that miR-934 is overexpressed only in triple-negative breast cancer, compared to luminal A, luminal B, and HER2 subtypes (Figure 6D). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.